

**Intellectual Property**

Patent pending

**Licensing opportunity**

New inhibitors for treating of symptoms of Alzheimer’s disease and other dementias

**Background**

Alzheimer's disease (AD) is a progressive neurodegenerative disorder of central nervous system. According to »World Alzheimer disease 2015«, 46.8 million people worldwide are living with dementia in 2015. This number will almost double every 20 years. The global costs of dementia have increased from US$ 604 billion in 2010 to US$ 818 billion in 2015, an increase of 35.4%.

**Description of the Invention**

The invention relates to novel inhibitors of butyrylcholinesterase which increase the concentration of neurotransmitter acetylcholine in the patients with AD and thereby improve their cognitive functions and memory.

**Main Advantages**

Inhibitors of butyrylcholinesterase are capable to alleviate the symptoms also in late stages of Alzheimer’s disease when currently available drugs are no longer active.



**Developed by**

Universitv of Ljubljana, Faculty of Pharmacy and Institut de Biologie Structurale

**Field of use**

Alzheimer's disease and other dementias

**Publication**

*Scientific Reports* 2016, 6, 39495

**Contact details**

Urša Jerše,

Phone: +386 2418528

E-mail: intelektualna.lastnina@uni-lj.si

www.uni-lj.si

**Current state of technology**

Laboratory tested, preclinical

**Reference**

UL20150787007